Ruzaltatug Biosimilar Antibody-Drug Conjugate (HER3) for Research

Cat No.: GMP-Bios-INN-1378

Anti-ERBB3/HER3 therapeutic antibody (Pre-made Ruzaltatug biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ruzaltatug (development code SHR-A2009) is a monoclonal antibody-drug conjugate targeting HER3 (ERBB3). It is developed by The First Affiliated Hospital of Zhengzhou University for Esophageal Cancer in Phase II development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1378-1mg 1mg 4635
GMP-Bios-INN-1378-10mg 10mg
GMP-Bios-INN-1378-100mg 100mg
GMP-Bios-INN-1378-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Ruzaltatug biosimilar, Whole mAb ADC, Anti-ERBB3/HER3 Antibody: Anti-ERBB3/ErbB3/HER3/Erbb-3 therapeutic antibody
INN Name Ruzaltatug
Target ERBB3/HER3
Format Whole mAb ADC
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC